U.S., Feb. 12 -- ClinicalTrials.gov registry received information related to the study (NCT06819215) titled 'Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients with Advanced Solid Tumors' on Jan. 20.
Brief Summary: This research is designed to determine if experimental treatment with PARP1 inhibitor, VB15010 is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.
Study Start Date: Oct. 30, 2024
Study Type: INTERVENTIONAL
Condition:
Cancer
Neoplasms
Neoplasms, Breast
Tumor
PARP
Ovarian Neoplasms
Prostatic Cancer
Pancreatic Cancer
Breast Cancer
Biliary Cancer
Colorectal Cancer
Intervention:
DRUG: VB15010
Oral PARP1 inhibitor
Recruitment Status: RECRUITING
Sponsor: Shenzhen Yangli Pharm...